 Frank Scott
Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 20 | 2023 | 290 | 7.490 |
Why?
| | Crohn Disease | 13 | 2022 | 197 | 4.690 |
Why?
| | Infliximab | 10 | 2022 | 94 | 1.800 |
Why?
| | Colitis, Ulcerative | 6 | 2021 | 105 | 1.780 |
Why?
| | Intestinal Obstruction | 3 | 2021 | 41 | 1.720 |
Why?
| | Gastrointestinal Agents | 3 | 2020 | 58 | 1.530 |
Why?
| | Immunosuppressive Agents | 6 | 2020 | 681 | 1.520 |
Why?
| | Gastroenterology | 4 | 2023 | 158 | 1.470 |
Why?
| | Tissue Adhesions | 3 | 2021 | 31 | 1.440 |
Why?
| | Tumor Necrosis Factor-alpha | 10 | 2023 | 1171 | 1.260 |
Why?
| | Adrenal Cortex Hormones | 4 | 2022 | 521 | 1.260 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2021 | 667 | 1.150 |
Why?
| | Intestine, Small | 2 | 2021 | 131 | 1.120 |
Why?
| | Algorithms | 6 | 2020 | 1541 | 1.030 |
Why?
| | JC Virus | 2 | 2015 | 23 | 1.010 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2015 | 39 | 0.990 |
Why?
| | Azathioprine | 5 | 2021 | 51 | 0.930 |
Why?
| | Biological Products | 3 | 2023 | 170 | 0.880 |
Why?
| | Esophageal Neoplasms | 6 | 2022 | 281 | 0.880 |
Why?
| | Abdomen | 2 | 2021 | 110 | 0.880 |
Why?
| | Abdominal Abscess | 1 | 2022 | 27 | 0.860 |
Why?
| | Anti-Bacterial Agents | 5 | 2018 | 1510 | 0.810 |
Why?
| | Gastrointestinal Hemorrhage | 3 | 2023 | 109 | 0.810 |
Why?
| | Antibodies, Viral | 2 | 2015 | 542 | 0.780 |
Why?
| | Ustekinumab | 1 | 2020 | 13 | 0.760 |
Why?
| | Humans | 75 | 2023 | 118974 | 0.760 |
Why?
| | Capsule Endoscopy | 1 | 2020 | 17 | 0.750 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2020 | 25 | 0.730 |
Why?
| | Biomedical Research | 2 | 2019 | 612 | 0.720 |
Why?
| | Barrett Esophagus | 4 | 2023 | 154 | 0.710 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 387 | 0.680 |
Why?
| | Quality-Adjusted Life Years | 5 | 2021 | 103 | 0.680 |
Why?
| | Intestinal Fistula | 1 | 2018 | 12 | 0.650 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 215 | 0.650 |
Why?
| | Colonic Diseases | 1 | 2018 | 26 | 0.640 |
Why?
| | Drug Utilization | 1 | 2019 | 169 | 0.640 |
Why?
| | Mass Screening | 4 | 2021 | 1052 | 0.640 |
Why?
| | Pericardium | 1 | 2018 | 50 | 0.630 |
Why?
| | Tuberculin Test | 1 | 2017 | 36 | 0.630 |
Why?
| | Health Resources | 1 | 2019 | 132 | 0.620 |
Why?
| | Cost-Benefit Analysis | 5 | 2021 | 554 | 0.620 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 73 | 0.620 |
Why?
| | Postoperative Complications | 2 | 2021 | 2235 | 0.610 |
Why?
| | Models, Statistical | 2 | 2019 | 636 | 0.610 |
Why?
| | Time-to-Treatment | 2 | 2019 | 149 | 0.610 |
Why?
| | Biological Factors | 2 | 2023 | 41 | 0.600 |
Why?
| | Latent Tuberculosis | 1 | 2017 | 69 | 0.580 |
Why?
| | Colorectal Neoplasms | 5 | 2022 | 628 | 0.570 |
Why?
| | Antibodies, Monoclonal | 4 | 2021 | 1284 | 0.560 |
Why?
| | Hospitalization | 3 | 2022 | 1785 | 0.550 |
Why?
| | Retrospective Studies | 21 | 2023 | 12978 | 0.550 |
Why?
| | Natalizumab | 1 | 2015 | 46 | 0.520 |
Why?
| | Male | 39 | 2022 | 57801 | 0.510 |
Why?
| | Mycobacterium tuberculosis | 1 | 2017 | 266 | 0.510 |
Why?
| | Heart Diseases | 1 | 2018 | 341 | 0.500 |
Why?
| | Aged | 26 | 2023 | 19657 | 0.490 |
Why?
| | Middle Aged | 29 | 2023 | 27617 | 0.490 |
Why?
| | Models, Theoretical | 1 | 2018 | 556 | 0.470 |
Why?
| | Adult | 27 | 2023 | 31512 | 0.470 |
Why?
| | Colonoscopy | 6 | 2022 | 208 | 0.470 |
Why?
| | Lymphoma | 1 | 2014 | 180 | 0.460 |
Why?
| | Age Factors | 4 | 2020 | 2995 | 0.450 |
Why?
| | Practice Patterns, Physicians' | 2 | 2019 | 1200 | 0.450 |
Why?
| | Markov Chains | 3 | 2020 | 118 | 0.450 |
Why?
| | Communicable Diseases | 1 | 2014 | 132 | 0.430 |
Why?
| | Adalimumab | 3 | 2021 | 43 | 0.430 |
Why?
| | Patient Discharge | 2 | 2023 | 796 | 0.420 |
Why?
| | United Kingdom | 5 | 2021 | 236 | 0.420 |
Why?
| | Risk Factors | 15 | 2022 | 9000 | 0.420 |
Why?
| | Professional Competence | 1 | 2012 | 91 | 0.400 |
Why?
| | Female | 35 | 2022 | 61565 | 0.400 |
Why?
| | Gastroenterologists | 2 | 2022 | 17 | 0.400 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 304 | 0.390 |
Why?
| | Research Design | 2 | 2019 | 969 | 0.380 |
Why?
| | Drug Therapy, Combination | 3 | 2020 | 965 | 0.380 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 42 | 0.380 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 610 | 0.370 |
Why?
| | Research Personnel | 1 | 2012 | 158 | 0.370 |
Why?
| | Gastroesophageal Reflux | 2 | 2023 | 248 | 0.360 |
Why?
| | Cohort Studies | 9 | 2021 | 5116 | 0.360 |
Why?
| | Proportional Hazards Models | 5 | 2021 | 1125 | 0.350 |
Why?
| | Quality of Life | 2 | 2021 | 2366 | 0.340 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2017 | 211 | 0.340 |
Why?
| | Pediatric Obesity | 1 | 2016 | 524 | 0.340 |
Why?
| | Skin Neoplasms | 1 | 2016 | 762 | 0.330 |
Why?
| | Adenoma | 2 | 2022 | 191 | 0.320 |
Why?
| | Electronic Health Records | 5 | 2022 | 829 | 0.310 |
Why?
| | Databases, Factual | 7 | 2018 | 1231 | 0.300 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2017 | 900 | 0.300 |
Why?
| | Mortality | 2 | 2020 | 299 | 0.300 |
Why?
| | Disease Management | 2 | 2021 | 571 | 0.290 |
Why?
| | Referral and Consultation | 2 | 2023 | 648 | 0.290 |
Why?
| | United States | 12 | 2021 | 12555 | 0.280 |
Why?
| | Patient Acceptance of Health Care | 2 | 2022 | 687 | 0.270 |
Why?
| | Aged, 80 and over | 10 | 2020 | 6561 | 0.270 |
Why?
| | Population Surveillance | 2 | 2021 | 413 | 0.270 |
Why?
| | Antifungal Agents | 2 | 2016 | 134 | 0.260 |
Why?
| | Case-Control Studies | 8 | 2021 | 3171 | 0.260 |
Why?
| | Recurrence | 5 | 2021 | 975 | 0.250 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 548 | 0.250 |
Why?
| | Delivery of Health Care | 2 | 2021 | 867 | 0.240 |
Why?
| | Esophageal Stenosis | 2 | 2014 | 47 | 0.240 |
Why?
| | Adenocarcinoma | 2 | 2021 | 812 | 0.240 |
Why?
| | Incidence | 7 | 2021 | 2424 | 0.240 |
Why?
| | Obesity | 1 | 2017 | 2746 | 0.230 |
Why?
| | Colectomy | 2 | 2021 | 84 | 0.230 |
Why?
| | Esophagitis, Peptic | 1 | 2023 | 18 | 0.230 |
Why?
| | Protective Factors | 2 | 2021 | 92 | 0.230 |
Why?
| | Models, Economic | 2 | 2020 | 48 | 0.230 |
Why?
| | Glucocorticoids | 2 | 2018 | 545 | 0.220 |
Why?
| | Treatment Outcome | 8 | 2021 | 9342 | 0.220 |
Why?
| | Cellulitis | 1 | 2022 | 47 | 0.210 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 734 | 0.210 |
Why?
| | Odds Ratio | 4 | 2018 | 996 | 0.210 |
Why?
| | Feces | 2 | 2022 | 396 | 0.200 |
Why?
| | Necrosis | 1 | 2022 | 230 | 0.200 |
Why?
| | Prognosis | 3 | 2019 | 3443 | 0.200 |
Why?
| | Rectal Fistula | 1 | 2021 | 21 | 0.200 |
Why?
| | Aftercare | 1 | 2023 | 194 | 0.200 |
Why?
| | Logistic Models | 5 | 2018 | 1901 | 0.200 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 49 | 0.190 |
Why?
| | Liver Transplantation | 2 | 2021 | 847 | 0.190 |
Why?
| | Spondylarthritis | 1 | 2021 | 35 | 0.190 |
Why?
| | Esophagoscopy | 2 | 2022 | 190 | 0.190 |
Why?
| | Cystectomy | 2 | 2017 | 32 | 0.190 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2020 | 32 | 0.190 |
Why?
| | Utilization Review | 1 | 2020 | 36 | 0.190 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 91 | 0.180 |
Why?
| | Tryptophan | 1 | 2021 | 139 | 0.180 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 31 | 0.180 |
Why?
| | Carcinoma | 1 | 2021 | 204 | 0.180 |
Why?
| | Metagenomics | 1 | 2021 | 134 | 0.180 |
Why?
| | Diabetes Mellitus | 2 | 2021 | 942 | 0.180 |
Why?
| | Urologic Surgical Procedures | 1 | 2021 | 94 | 0.180 |
Why?
| | Obesity, Morbid | 1 | 2023 | 197 | 0.180 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2674 | 0.180 |
Why?
| | Metabolomics | 2 | 2022 | 550 | 0.170 |
Why?
| | Hospitals | 2 | 2021 | 598 | 0.170 |
Why?
| | Surveys and Questionnaires | 5 | 2021 | 4708 | 0.170 |
Why?
| | Deglutition Disorders | 1 | 2021 | 131 | 0.170 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 325 | 0.170 |
Why?
| | Job Satisfaction | 1 | 2021 | 175 | 0.170 |
Why?
| | Chronic Disease | 2 | 2022 | 1636 | 0.170 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2021 | 210 | 0.170 |
Why?
| | Follow-Up Studies | 3 | 2019 | 4596 | 0.170 |
Why?
| | Hospitals, Veterans | 1 | 2020 | 246 | 0.170 |
Why?
| | Diverticulum | 1 | 2018 | 11 | 0.170 |
Why?
| | Hematemesis | 1 | 2018 | 3 | 0.160 |
Why?
| | Health Care Costs | 1 | 2021 | 394 | 0.160 |
Why?
| | Symptom Assessment | 2 | 2017 | 123 | 0.160 |
Why?
| | Prevalence | 3 | 2021 | 2326 | 0.160 |
Why?
| | Vascular Surgical Procedures | 1 | 2021 | 262 | 0.160 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 132 | 0.160 |
Why?
| | Arthritis, Rheumatoid | 2 | 2016 | 989 | 0.160 |
Why?
| | Clostridium Infections | 1 | 2018 | 57 | 0.160 |
Why?
| | Intestines | 1 | 2021 | 332 | 0.160 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2017 | 26 | 0.150 |
Why?
| | Fatal Outcome | 1 | 2018 | 287 | 0.150 |
Why?
| | Risk Assessment | 3 | 2016 | 3057 | 0.150 |
Why?
| | Cystadenoma, Mucinous | 1 | 2016 | 12 | 0.140 |
Why?
| | Continuity of Patient Care | 1 | 2019 | 265 | 0.140 |
Why?
| | Colonic Polyps | 1 | 2017 | 70 | 0.140 |
Why?
| | Itraconazole | 1 | 2016 | 7 | 0.140 |
Why?
| | Budesonide | 1 | 2016 | 85 | 0.140 |
Why?
| | Pharmacoepidemiology | 1 | 2015 | 21 | 0.140 |
Why?
| | Pancreatic Diseases | 1 | 2016 | 63 | 0.140 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2023 | 202 | 0.140 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2016 | 58 | 0.140 |
Why?
| | Guideline Adherence | 1 | 2020 | 523 | 0.140 |
Why?
| | Neoplasms | 2 | 2023 | 2179 | 0.140 |
Why?
| | Cysts | 1 | 2016 | 93 | 0.130 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 93 | 0.130 |
Why?
| | Data Accuracy | 1 | 2015 | 56 | 0.130 |
Why?
| | Antirheumatic Agents | 1 | 2018 | 254 | 0.130 |
Why?
| | Hyperlipidemias | 1 | 2016 | 128 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2021 | 330 | 0.130 |
Why?
| | Psoriasis | 1 | 2016 | 76 | 0.130 |
Why?
| | Arthritis, Juvenile | 1 | 2015 | 42 | 0.130 |
Why?
| | Polypharmacy | 1 | 2015 | 75 | 0.130 |
Why?
| | Hedgehog Proteins | 1 | 2016 | 175 | 0.130 |
Why?
| | Microbiota | 1 | 2022 | 656 | 0.120 |
Why?
| | Cholesterol | 1 | 2016 | 373 | 0.120 |
Why?
| | Dilatation | 1 | 2014 | 56 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2017 | 736 | 0.120 |
Why?
| | Prescription Drugs | 1 | 2015 | 113 | 0.120 |
Why?
| | Anastomosis, Surgical | 1 | 2014 | 146 | 0.120 |
Why?
| | Young Adult | 6 | 2019 | 10793 | 0.120 |
Why?
| | Immunologic Factors | 1 | 2016 | 225 | 0.120 |
Why?
| | Streptococcal Infections | 1 | 2016 | 141 | 0.120 |
Why?
| | Early Detection of Cancer | 3 | 2022 | 360 | 0.120 |
Why?
| | Virus Diseases | 1 | 2016 | 198 | 0.120 |
Why?
| | Disease Progression | 2 | 2021 | 2490 | 0.120 |
Why?
| | Radiation Injuries | 1 | 2014 | 131 | 0.110 |
Why?
| | Registries | 1 | 2021 | 1810 | 0.110 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 589 | 0.110 |
Why?
| | Foreign Bodies | 1 | 2014 | 98 | 0.110 |
Why?
| | Primary Health Care | 2 | 2022 | 1560 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1244 | 0.110 |
Why?
| | Tissue and Organ Procurement | 1 | 2015 | 248 | 0.110 |
Why?
| | Epidemiology | 1 | 2012 | 15 | 0.110 |
Why?
| | Biomarkers | 2 | 2020 | 3588 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2013 | 218 | 0.100 |
Why?
| | Endoscopy | 1 | 2014 | 272 | 0.100 |
Why?
| | Age Distribution | 1 | 2012 | 362 | 0.100 |
Why?
| | Research Support as Topic | 1 | 2012 | 114 | 0.100 |
Why?
| | Adolescent | 6 | 2019 | 18480 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1868 | 0.100 |
Why?
| | Veterans | 1 | 2021 | 1208 | 0.100 |
Why?
| | Physicians | 1 | 2019 | 794 | 0.100 |
Why?
| | Infant | 4 | 2016 | 8293 | 0.090 |
Why?
| | Child, Preschool | 4 | 2016 | 9491 | 0.090 |
Why?
| | Medicare | 3 | 2021 | 663 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 4552 | 0.080 |
Why?
| | Child | 4 | 2022 | 19129 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 1865 | 0.080 |
Why?
| | Laparoscopy | 1 | 2012 | 417 | 0.080 |
Why?
| | Neoplasm Staging | 2 | 2022 | 1223 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2020 | 842 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2016 | 1965 | 0.060 |
Why?
| | Prospective Studies | 3 | 2023 | 6471 | 0.060 |
Why?
| | Survival Analysis | 2 | 2017 | 1267 | 0.060 |
Why?
| | Regression Analysis | 2 | 2017 | 983 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 6412 | 0.060 |
Why?
| | Gastrectomy | 1 | 2023 | 82 | 0.050 |
Why?
| | Cost Savings | 1 | 2021 | 77 | 0.050 |
Why?
| | Granzymes | 1 | 2021 | 40 | 0.050 |
Why?
| | Training Support | 1 | 2021 | 24 | 0.050 |
Why?
| | Documentation | 1 | 2023 | 175 | 0.050 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 54 | 0.050 |
Why?
| | Morbidity | 1 | 2021 | 296 | 0.050 |
Why?
| | Perception | 1 | 2022 | 314 | 0.050 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 176 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2874 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 205 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 147 | 0.040 |
Why?
| | Medicine | 1 | 2021 | 106 | 0.040 |
Why?
| | Physician's Role | 1 | 2021 | 200 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 331 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 467 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 279 | 0.040 |
Why?
| | Career Choice | 1 | 2021 | 192 | 0.040 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 79 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2018 | 13 | 0.040 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 178 | 0.040 |
Why?
| | Mathematical Concepts | 1 | 2018 | 24 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2021 | 422 | 0.040 |
Why?
| | Margins of Excision | 1 | 2017 | 31 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1419 | 0.040 |
Why?
| | Societies, Medical | 1 | 2021 | 703 | 0.040 |
Why?
| | Prednisone | 1 | 2018 | 235 | 0.040 |
Why?
| | Mercaptopurine | 1 | 2016 | 15 | 0.040 |
Why?
| | Etanercept | 1 | 2016 | 51 | 0.040 |
Why?
| | Hip Fractures | 1 | 2018 | 79 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 588 | 0.040 |
Why?
| | Survival Rate | 1 | 2021 | 1720 | 0.040 |
Why?
| | Decision Making | 1 | 2023 | 809 | 0.040 |
Why?
| | Weight Loss | 1 | 2021 | 655 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 52 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 683 | 0.030 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 531 | 0.030 |
Why?
| | Streptococcus pyogenes | 1 | 2016 | 35 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 380 | 0.030 |
Why?
| | Methotrexate | 1 | 2016 | 227 | 0.030 |
Why?
| | Bias | 1 | 2016 | 198 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 403 | 0.030 |
Why?
| | Pennsylvania | 1 | 2014 | 101 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 462 | 0.030 |
Why?
| | Mental Recall | 1 | 2015 | 180 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1597 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2016 | 248 | 0.030 |
Why?
| | Anticoagulants | 1 | 2018 | 559 | 0.030 |
Why?
| | Waiting Lists | 1 | 2015 | 228 | 0.030 |
Why?
| | Medicaid | 1 | 2018 | 411 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 922 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1774 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1440 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1474 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 331 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1781 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 1798 | 0.020 |
Why?
|
|
Scott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|